Briefing Chat: How Dolly Parton left her mark on science

Nature正文已收录本站
  • NATURE PODCAST

Nature reporters discuss the country-music icon's advocacy for vaccines and public health — plus, promising trial results for an mRNA cancer therapy.

By

  1. Benjamin Thompson
  2. Elizabeth Gibney

Download the Nature Briefing Podcast 28 August 2026

In this episode:

00:18 Researchers celebrate Dolly Parton's contributions to science

Nature: Dolly Parton dies aged 80 — researchers celebrate her contributions to science

08:40 Phase III trial of melanoma vaccine shows promise

Nature: Moderna cancer vaccine stops melanoma returning: what’s next for personalized treatments?

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Never miss an episode. Subscribe to the Nature Podcast on Apple Podcasts, Spotify, YouTube Music or your favourite podcast app. An RSS feed for the Nature Podcast is available too.

doi: https://doi.org/10.1038/d41586-026-02732-w

  • Dolly at 20: The inside story on the world’s most famous sheep

  • Music is not a universal language — but it can bring us together when words fail

  • How personalized cancer vaccines could keep tumours from coming back

Subjects

Latest on:

  • Communication
  • Funding
  • Cancer
  • Dolly Parton dies aged 80 — researchers celebrate her contributions to science

    News

  • Ancient surveying instrument found in Egypt

    News & Views

  • Science-backed tips on how to avoid distractions

    Career Feature

  • Dolly Parton dies aged 80 — researchers celebrate her contributions to science

    News

  • A guide to securing your first research fellowship: what reviewers are looking for

    Career Column

  • Frontier-technology markets are too narrow — here’s how to widen them

    Comment

  • The Moderna cancer vaccine offers hope — now we must speed up personalized therapies

    World View

  • A binding-to-release strategy for targeted anticancer drug delivery

    Article

  • Sleuth identifies dozens of studies that used the wrong antibody

    News